Table 1.

FDA-approved vascular endothelial growth factor signaling pathway inhibitors

Drug (brand name)	Molecular targets	FDA approved for the treatment of
Aflibercept (Zaltrap)	Recombinant fusion protein of FLT-1 (VEGF receptor 1) and KDR (VEGF receptor 2) and immunoglobulin Fc component that captures (traps) VEGF-A, VEGF-B, and placental growth factor	Metastatic colorectal cancer
Axitinib (Inlyta)	c-KIT, PDGFR-A, PDGFR-B, FLT-1, KDR, FLT-4 (VEGF receptor 3)	Advanced renal cell carcinoma
Bevacizumab (Avastin)	Anti-VEGF-A antibody	Glioblastoma Persistent/recurrent/metastatic cervical cancer Metastatic colorectal cancer Non-small (nonsquamous) cell lung cancer Ovarian (epithelial), fallopian tube, or primary peritoneal cancer Metastatic renal cell cancer
Cabozantinib (Cabometyx Cometrig)	MET, KDR, FLT3, c-KIT, RET	Advanced renal cell carcinoma Medullary, locally advanced or metastatic thyroid cancer
Lenvatinib (Lenvima)	PDGFR-B, FLT-1, KDR, FLT-4, RET, c-KIT	Advanced renal cell carcinoma Advanced thyroid cancer
Pazopanib (Votrient)	ABL-1, c-KIT, PDGFR-A, PDGFR-B, FLT-1, KDR, FLT-4, FGFR, c-fms	Advanced renal cell cancer Advanced soft tissue sarcoma
Ramucirumab (Cyramza)	Anti-KDR antibody	Metastatic non-small cell lung Metastatic gastric Metastatic colorectal cancer
Regorafenib (Stivarga)	PDGFR-B, FLT-1, KDR, FLT-4, TIE2, RET, c-KIT, RAF	Metastatic colorectal cancer, locally-advanced, unresectable, or metastatic gastrointestinal stromal tumor, and hepatocellular carcinoma
Sorafenib (Nexavar)	B-Raf, FLT-1, FLT-3, FLT-4, KDR, KIT, PDGFR-A, PDGFR-B, FGFR, c-fms	Hepatocellular carcinoma Advanced renal cell cancer Differentiated thyroid cancer
Sunitinib (Sutent)	ABL-1, c-KIT, PDGFR-A, PDGFR-B, FLT-1, KDR, FLT-3, FLT-4, FGFR, SRC, c-smc	Gastrointestinal stromal tumor Pancreatic neuroendocrine tumors Renal cell cancer, adjuvant and advance
Vandetanib (Candetanib)	EGFR, KDR, FLT-4, RET	Medullary, locally advanced or metastatic thyroid cancer